ByTrending Posts
Merck’s First Fully AI-Designed Oncology Drug: 2027 China…
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital…
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution…
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution…
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline…
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
Qure.ai Secures Landmark FDA Clearance for qXR-Detect, Cementing…
Mumbai, India – March 4, 2026 – Qure.ai, a global leader in AI-powered radiology, today celebrated FDA clearance for…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication…
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Ardent Health’s Hellocare.ai Virtual Nursing Play: 20% Readmission…
Ardent Health’s March 3-4, 2026, partnership with Hellocare.ai deploys AI modules for virtual nursing, telehealth, and real-time patient…
VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster…
The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…
Trending Posts
Latest Stories
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1…
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology,…
Gallery
